GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Gross Profit

Kintor Pharmaceutical (HKSE:09939) Gross Profit : HK$-44.98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Gross Profit?

Kintor Pharmaceutical's gross profit for the six months ended in Dec. 2023 was HK$-46.19 Mil. Kintor Pharmaceutical's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-44.98 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Kintor Pharmaceutical's gross profit for the six months ended in Dec. 2023 was HK$-46.19 Mil. Kintor Pharmaceutical's Revenue for the six months ended in Dec. 2023 was HK$0.00 Mil. Therefore, Kintor Pharmaceutical's Gross Margin % for the quarter that ended in Dec. 2023 was %.

Kintor Pharmaceutical had a gross margin of % for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 6 years, the highest Gross Margin % of Kintor Pharmaceutical was 1.26%. The lowest was 1.26%. And the median was 1.26%.


Kintor Pharmaceutical Gross Profit Historical Data

The historical data trend for Kintor Pharmaceutical's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Gross Profit Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial - - 41.92 - -46.19

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -46.19 1.21

Competitive Comparison of Kintor Pharmaceutical's Gross Profit

For the Biotechnology subindustry, Kintor Pharmaceutical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Gross Profit distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Gross Profit falls into.



Kintor Pharmaceutical Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Kintor Pharmaceutical's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 46.189
=-46.19

Kintor Pharmaceutical's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 46.189
=-46.19

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-44.98 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Kintor Pharmaceutical's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=-46.19 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Kintor Pharmaceutical  (HKSE:09939) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Kintor Pharmaceutical had a gross margin of % for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Kintor Pharmaceutical Gross Profit Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines